A Phase 3 interventional study of 20-valent pneumococcal conjugate vaccine and 13-valent pneumococcal conjugate vaccine in Pneumococcal Disease, sponsored by Pfizer. Completed at 66 sites in 12 countries. Open to participants aged 42 Days to 112 Days, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-01-08.
Sponsored by Pfizer · Phase 3, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections — 2 open to participants now, 3 under way, 1 of them phase 3. Pneumococcal 20-Valent Conjugate Vaccine · Pneumococcal Infections.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, this one is the 6th largest by enrollment, is one of 5 that started in 2020, is one of 14 in phase 3, and was the 6th registered.
299 studies on the registry are indexed under Pneumococcal Infections; 26 are open to participants now.
Browse Pneumococcal Infections studies →2 of the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections are open now, in 2 countries. Recruiting first, the newest first:
Pfizer · Sites in China
Ages 42 days–98 days · Healthy volunteers
Merck Sharp & Dohme LLC · Sites in United States
Ages 2 mo–15 mo · Healthy volunteers
By country, each count listing its studies:
Pneumococcal 20-Valent Conjugate Vaccine: first FDA approval 2021 (Prevnar 20). What it is approved for, and how studies give it, is on its page →
Of the 20 Pneumococcal Infections studies recruiting now, 4 (20%) set no upper age limit and 14 (70%) stop at 75 or younger; 14 take children under 18; 16 take healthy volunteers.
This study: 42 Days to 112 Days · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
19 studies; the count open now beside each. This study's row is marked.
First in 2018; this study’s year is marked. 5 started in 2020.
This study's enrollment of 1,258 is above the median of 379 across 254 interventional studies indexed under Pneumococcal Infections.
Median enrollment 668 across the 19 interventional studies. Of the 15 that completed or were terminated, 13 (87%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 19 have an industry lead sponsor. The 4 most frequent:
Pfizer is the lead sponsor of 3,337 studies on the registry; 148 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
75 studies in Pneumococcal Infections by Pfizer: 4 open now, 8 under way, 5 of them phase 3. Of 67 finished, 45 (67%) have results posted.
Among the 75 studies in Pneumococcal Infections by Pfizer, this one is the 15th largest by enrollment of the 57 interventional ones that give a count, is one of 6 that started in 2020, is one of 33 in phase 3, and was the 51st registered.
Pfizer’s Pneumococcal Infections studies by the year they started, since 2001.
1 of the studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07023081PfizerA Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant | 2027-06-10 |
Add it to your calendar (.ics) → With an account.
Among the 19 studies testing Pneumococcal 20-Valent Conjugate Vaccine in Pneumococcal Infections, from their registry updates:
Among Pfizer’s 75 in Pneumococcal Infections:
This tab as a report to print or save as PDF → With an account.
20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Pneumococcal conjugate vaccine
Biological: 20-valent pneumococcal conjugate vaccine
Pneumococcal conjugate vaccine
Biological: 13-valent pneumococcal conjugate vaccine
20-valent pneumococcal conjugate vaccine
13-valent pneumococcal conjugate vaccine
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Primary Study Population
Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.
Time frame: Within 7 days after Dose 1
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Primary Study Population
Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 days after Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Primary Study Population
Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 days after Dose 3
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Primary Study Population
Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: was defined as temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 Days after Dose 1
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Primary Study Population
Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever: was defined as temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 Days after Dose 2
Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Primary Study Population
Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: was defined as temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) \& severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 Days after Dose 3
Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: Primary Study Population
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.
Time frame: From Dose 1 to 1 month after Dose 2
Percentage of Participants With Adverse Events (AEs) From Dose 3 to 1 Month After Dose 3: Primary Study Population
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.
Time frame: From Dose 3 to 1 month after Dose 3
Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 3: Primary Study Population
A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.
Time frame: From Dose 1 to 1 month after Dose 3
Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) From Dose 1 to 1 Month After Dose 3: Primary Study Population
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.
Time frame: From Dose 1 to 1 month after Dose 3
Percentage of Participants With Predefined Pneumococcal Immunoglobulin G (IgG) Antibody 1 Month After Dose 2: Primary Study Population
Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per mL (mcg/mL), for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.
Time frame: 1 month after Dose 2
Geometric Mean Concentration (GMC) of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 2: Primary Study Population
Pneumococcal serotype-specific IgG concentration was measured for serum sample for 13vPnC serotype: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 7 additional serotype: 8, 10A, 11A, 12F, 15B, 22F, 33F. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, corresponding 2-sided 95% CIs (based on Student's t distribution). Assay result below LLOQ was set to 0.5\*LLOQ. Geometric mean ratios (GMRs) were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CIs (based on Student's t distribution).
Time frame: 1 month after Dose 2
GMC of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 3: Primary Study Population
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 7 additional serotype: 8, 10A, 11A, 12F, 15B, 22F,33F. GMC and corresponding 2-sided 95% CI were calculated by exponentiating mean logarithm of concentrations and corresponding 2-sided 95% CI (based on Student's t distribution). Assay result below LLOQ were set to 0.5\*LLOQ. GMRs were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CI (based on Student's t distribution).
Time frame: 1 month after Dose 3
Percentage of Participants With Predefined Antibody Levels for Concomitant Vaccine Antigens 1 Month After Dose 3: Primary Study Population
Diphtheria and tetanus toxoids: concentration of antibody (AB) (in international units \[IU\]) to diphtheria \& tetanus toxoid (prespecified level\>=0.1 IU/mL); Pertussis antigens-pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN): prespecified level \>=observed Anti pertussis Antibody concentration achieved by 95% of 13vPnC recipient; HBsAg prespecified level \>=10 milli-IU per mL (mIU/mL); Poliovirus strains (types 1, 2 and 3): prespecified level: \>=1:8; Hemophilus influenzae type b(Hib): prespecified level \>=0.15 microgram per millilitre (mcg/mL) polyribosylribitol phosphate (anti-PRP) in mcg/mL. Concomitant vaccine response was assessed from subset of randomly selected study participants.
Time frame: 1 month after Dose 3
GMC of Measles Virus Antibody 1 Month After Dose 3: Primary Study Population
Pre-specified vaccine antigen (measles) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.
Time frame: 1 month after Dose 3
GMC of Mumps Virus Antibody 1 Month After Dose 3: Primary Study Population
Pre-specified vaccine antigen (mumps) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.
Time frame: 1 month after Dose 3
GMC of Rubella Virus Antibody 1 Month After Dose 3: Primary Study Population
Pre-specified vaccine antigen (rubella) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.
Time frame: 1 month after Dose 3
GMC of Varicella Virus Antibody 1 Month After Dose 3: Primary Study Population
Pre-specified vaccine antigen (varicella) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.
Time frame: 1 month after Dose 3
Percentage of Participants With Local Reactions Within 7 Days After Dose 1: Russian Cohort
Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\> 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 days after Dose 1
Percentage of Participants With Local Reactions Within 7 Days After Dose 2: Russian Cohort
Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\> 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 days after Dose 2
Percentage of Participants With Local Reactions Within 7 Days After Dose 3: Russian Cohort
Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\> 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.
Time frame: Within 7 days after Dose 3
Percentage of Participants With Systemic Events Within 7 Days After Dose 1: Russian Cohort
Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using e-diary. Fever: temperature \>=38.0 degree C \& categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.
Time frame: Within 7 Days after Dose 1
Percentage of Participants With Systemic Events Within 7 Days After Dose 2: Russian Cohort
Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.
Time frame: Within 7 Days after Dose 2
Percentage of Participants With Systemic Events Within 7 Days After Dose 3: Russian Cohort
Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.
Time frame: Within 7 Days after Dose 3
Percentage of Participants With AEs From Dose 1 to 1 Month After Dose 2: Russian Cohort
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.
Time frame: From Dose 1 to 1 month after Dose 2
Percentage of Participants With AEs From Dose 3 to 1 Month After Dose 3: Russian Cohort
An AE was any untoward medical occurrence in a participants, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.
Time frame: From Dose 3 to 1 month after Dose 3
Percentage of Participants With SAEs From Dose 1 to 1 Month After Dose 3: Russian Cohort
A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.
Time frame: From Dose 1 to 1 month after Dose 3
Percentage of Participants With NDCMC From Dose 1 to 1 Month After Dose 3: Russian Cohort
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.
Time frame: From Dose 1 to 1 month after Dose 3
Percentage of Participants With Predefined Pneumococcal IgG Antibody 1 Month After Dose 2: Russian Cohort
Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 mcg/mL, for serotype 5: \>=0.23 mcg/mL, for serotype 6B. \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.
Time frame: 1 month after Dose 2
GMC of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 2: Russian Cohort
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and 7 additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, 33F. Assay results below the LLOQ were set to 0.5 \* LLOQ. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, and the corresponding 2-sided 95% CIs (based on Student's t distribution).
Time frame: 1 month after Dose 2
GMC of Serotype-specific Pneumococcal IgG Antibody 1 Month After Dose 3: Russian Cohort
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and additional serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. Assay results below the LLOQ were set to 0.5 \* LLOQ. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, and the corresponding 2-sided 95% CIs (based on Student's t distribution).
Time frame: 1 month after Dose 3
Percentage of Participants With Predefined Pneumococcal IgG Antibody 1 Month After Dose 3: Primary Study Population
Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 mcg/mL, for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.
Time frame: 1 Month after Dose 3
Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) 1 Month After Dose 2: Primary Study Population
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 2. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the Student's t distribution.
Time frame: 1 month after Dose 2
Geometric Mean Titers (GMTs) of Serotype-specific Opsonophagocytic Activity (OPA) 1 Month After Dose 3: Primary Study Population
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 3. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the Student's t distribution.
Time frame: 1 Month after Dose 3
Geometric Mean Fold Rise (GMFRs) of IgG Concentrations From Before Dose 3 to 1 Month After Dose 3: Primary Study Population
20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs (based on the Student's t distribution).
Time frame: Before Dose 3 to 1 month after Dose 3
Percentage of Participants With Predefined Antibody Levels for Concomitant Vaccine Antigens 1 Month After Dose 2: Primary Study Population
Pre-specified vaccines were administered concomitantly with 20vPnC or 13vPnC and responses assessed using pre-defined levels as follows: Diphtheria and tetanus toxoids: concentration of antibody (in international units \[IU\]) to diphtheria and tetanus toxoid (prespecified level \>= observed anti-pertussis antibody concentration achieved by 95% of 13vPnC recipients); Poliomyelitis: NA titers to poliovirus types 1, 2, and 3 (prespecified level NA titer \>=1:8); and Hib: concentration of antibody to Hib (PRP) in mcg/mL (prespecified level \>=0.15 mcg/mL anti-PRP). 2-sided 95% CI was based on Clopper and Pearson method. The assays were performed on randomly selected subsets.
Time frame: 1 month after Dose 2
Percentage of Participants With Predefined Pneumococcal IgG Antibody 1 Month After Dose 3: Russian Cohort
Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 mcg/mL, for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.
Time frame: 1 Month after Dose 3
GMTs of Serotype-specific OPA at 1 Month After Dose 2: Russian Cohort
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 2. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the student's t distribution.
Time frame: 1 month after Dose 2
GMTs of Serotype-specific OPA at 1 Month After Dose 3: Russian Cohort
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 3. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the student's t distribution.
Time frame: 1 Month after Dose 3
| Milestone | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|---|---|
| Started | 601 | 603 | 24 | 27 |
| Dose 1 | 601 | 603 | 24 | 27 |
| Dose 2 | 593 | 598 | 24 | 27 |
| Dose 3 | 588 | 594 | 22 | 25 |
| Completed | 583 | 590 | 22 | 25 |
| Not completed | 18 | 13 | 2 | 2 |
| Withdrew: Protocol violation | 1 | 1 | 0 | 0 |
| Withdrew: Adverse event | 3 | 0 | 0 | 0 |
| Withdrew: Lost to follow-up | 5 | 4 | 0 | 0 |
| Withdrew: No longer met eligibility criteria | 3 | 3 | 1 | 1 |
| Withdrew: Withdrawal by parent/guardian | 6 | 5 | 1 | 1 |
Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an electronic diary (e-diary). Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 centimeter (cm). Redness and swelling were graded as mild (greater than \[\>\] 0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95 percent (%) confidence interval (CI) was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Redness: Mild | 20.7 ± 17.6 | 22.7 ± 19.4 |
| Redness: Moderate | 4.5 ± 3.0 | 4.8 ± 3.2 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Mild | 12.7 ± 10.1 | 12.9 ± 10.4 |
| Swelling: Moderate | 8.7 ± 6.6 | 7.3 ± 5.4 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Pain at Injection Site: Mild | 16.7 ± 13.8 | 17.9 ± 14.9 |
| Pain at Injection Site: Moderate | 12.0 ± 9.5 | 11.4 ± 9.0 |
| Pain at Injection Site: Severe | 0.3 ± 0.0 | 0 ± 0.0 |
Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Redness: Mild | 24.8 ± 21.4 | 22.9 ± 19.6 |
| Redness: Moderate | 3.7 ± 2.3 | 5.1 ± 3.4 |
| Redness: Severe | 0 ± 0.0 | 0.2 ± 0.0 |
| Swelling: Mild | 13.7 ± 11.0 | 14.1 ± 11.4 |
| Swelling: Moderate | 8.3 ± 6.2 | 6.2 ± 4.4 |
| Swelling: Severe | 0 ± 0.0 | 0.2 ± 0.0 |
| Pain at Injection Site: Mild | 13.3 ± 10.7 | 16.5 ± 13.6 |
| Pain at Injection Site: Moderate | 9.3 ± 7.1 | 7.9 ± 5.9 |
| Pain at Injection Site: Severe | 0.2 ± 0.0 | 0.2 ± 0.0 |
Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\>2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Redness: Mild | 23.3 ± 19.9 | 25.1 ± 21.6 |
| Redness: Moderate | 13.4 ± 10.8 | 8.5 ± 6.4 |
| Redness: Severe | 0.2 ± 0.0 | 0.2 ± 0.0 |
| Swelling: Mild | 17.8 ± 14.7 | 14.5 ± 11.8 |
| Swelling: Moderate | 11.9 ± 9.4 | 9.7 ± 7.5 |
| Swelling: Severe | 0.2 ± 0.0 | 0.3 ± 0.0 |
| Pain at Injection Site: Mild | 24.7 ± 21.2 | 22.4 ± 19.0 |
| Pain at Injection Site: Moderate | 17.4 ± 14.4 | 17.2 ± 14.3 |
| Pain at Injection Site: Severe | 0.3 ± 0.0 | 0.3 ± 0.0 |
Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: was defined as temperature \>=38.0 degree Celsius (C) and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Fever: >=38.0 degrees C to 38.4 degrees C | 7.5 ± 5.5 | 6.8 ± 4.9 |
| Fever: >38.4 degrees C to 38.9 degrees C | 1.3 ± 0.6 | 1.3 ± 0.6 |
| Fever: >38.9 degrees C to 40.0 degrees C | 0 ± 0.0 | 0.3 ± 0.0 |
| Fever: >40.0 degrees C | 0 ± 0.0 | 0 ± 0.0 |
| Decreased appetite: Mild | 16.2 ± 13.4 | 13.3 ± 10.7 |
| Decreased appetite: Moderate | 7.5 ± 5.5 | 8.8 ± 6.7 |
| Decreased appetite: Severe | 1.0 ± 0.4 | 0.5 ± 0.1 |
| Drowsiness: Mild | 46.0 ± 41.9 | 48.6 ± 44.5 |
| Drowsiness: Moderate | 14.4 ± 11.7 | 14.3 ± 11.6 |
| Drowsiness: Severe | 0.8 ± 0.3 | 0.8 ± 0.3 |
| Irritability: Mild | 17.6 ± 14.6 | 17.4 ± 14.5 |
| Irritability: Moderate | 46.2 ± 42.1 | 46.4 ± 42.4 |
| Irritability: Severe | 8.2 ± 6.1 | 8.6 ± 6.5 |
Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using an e-diary. Fever: was defined as temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Fever: >=38.0 degrees C to 38.4 degrees C | 11.7 ± 9.2 | 11.6 ± 9.2 |
| Fever: >38.4 degrees C to 38.9 degrees C | 2.5 ± 1.4 | 2.0 ± 1.0 |
| Fever: >38.9 degrees C to 40.0 degrees C | 0.7 ± 0.2 | 0.3 ± 0.0 |
| Fever: >40.0 degrees C | 0 ± 0.0 | 0 ± 0.0 |
| Decreased appetite: Mild | 13.5 ± 10.9 | 12.1 ± 9.6 |
| Decreased appetite: Moderate | 10.1 ± 7.8 | 6.4 ± 4.6 |
| Decreased appetite: Severe | 1.0 ± 0.4 | 0.8 ± 0.3 |
| Drowsiness: Mild | 37.8 ± 33.9 | 37.0 ± 33.1 |
| Drowsiness: Moderate | 13.2 ± 10.6 | 13.5 ± 10.8 |
| Drowsiness: Severe | 0.3 ± 0.0 | 0.2 ± 0.0 |
| Irritability: Mild | 22.8 ± 19.5 | 21.2 ± 18.0 |
| Irritability: Moderate | 43.1 ± 39.0 | 40.6 ± 36.6 |
| Irritability: Severe | 5.7 ± 4.0 | 6.6 ± 4.7 |
Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: was defined as temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) \& severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Fever: >=38.0 degrees C to 38.4 degrees C | 13.4 ± 10.8 | 13.5 ± 10.8 |
| Fever: >38.4 degrees C to 38.9 degrees C | 6.9 ± 5.0 | 7.0 ± 5.1 |
| Fever: >38.9 degrees C to 40.0 degrees C | 3.6 ± 2.3 | 3.2 ± 2.0 |
| Fever: >40.0 degrees C | 0.3 ± 0.0 | 0 ± 0.0 |
| Decreased appetite: Mild | 20.0 ± 16.8 | 15.5 ± 12.7 |
| Decreased appetite: Moderate | 17.1 ± 14.1 | 18.9 ± 15.8 |
| Decreased appetite: Severe | 2.2 ± 1.2 | 2.0 ± 1.1 |
| Drowsiness: Mild | 34.8 ± 30.9 | 32.8 ± 29.0 |
| Drowsiness: Moderate | 15.3 ± 12.5 | 14.7 ± 11.9 |
| Drowsiness: Severe | 0.7 ± 0.2 | 1.2 ± 0.5 |
| Irritability: Mild | 23.4 ± 20.1 | 21.3 ± 18.1 |
| Irritability: Moderate | 43.4 ± 39.4 | 45.4 ± 41.3 |
| Irritability: Severe | 4.1 ± 2.7 | 4.1 ± 2.6 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) From Dose 1 to 1 Month After Dose 2: Primary Study Population | 13.8 ± 11.2 | 14.4 ± 11.7 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Percentage of Participants With Adverse Events (AEs) From Dose 3 to 1 Month After Dose 3: Primary Study Population | 15.5 ± 12.6 | 16.5 ± 13.6 |
A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Percentage of Participants With Serious Adverse Events (SAEs) From Dose 1 to 1 Month After Dose 3: Primary Study Population | 5.7 ± 3.9 | 6.6 ± 4.8 |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Percentage of Participants With Newly Diagnosed Chronic Medical Condition (NDCMC) From Dose 1 to 1 Month After Dose 3: Primary Study Population | 1.0 ± 0.4 | 1.0 ± 0.4 |
Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 microgram per mL (mcg/mL), for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Serotype 1 | 70.7 (66.7 to 74.4) | 84.2 (80.9 to 87.1) |
| Serotype 3 | 58.0 (53.8 to 62.1) | 75.8 (72.0 to 79.3) |
| Serotype 4 | 68.6 (64.5 to 72.4) | 79.5 (76.0 to 82.8) |
| Serotype 5 | 63.4 (59.3 to 67.4) | 76.0 (72.2 to 79.5) |
| Serotype 6A | 59.5 (55.4 to 63.6) | 73.7 (69.8 to 77.3) |
| Serotype 6B | 20.7 (17.5 to 24.3) | 36.5 (32.5 to 40.7) |
| Serotype 7F | 87.6 (84.6 to 90.2) | 90.2 (87.5 to 92.5) |
| Serotype 9V | 60.2 (56.1 to 64.3) | 74.6 (70.7 to 78.1) |
| Serotype 14 | 78.6 (75.0 to 81.9) | 81.9 (78.4 to 85.0) |
| Serotype 18C | 71.0 (67.1 to 74.7) | 76.5 (72.8 to 80.0) |
| Serotype 19A | 92.2 (89.7 to 94.3) | 94.0 (91.6 to 95.8) |
| Serotype 19F | 94.3 (92.1 to 96.1) | 95.7 (93.7 to 97.2) |
| Serotype 23F | 23.5 (20.1 to 27.2) | 41.8 (37.7 to 46.0) |
| Serotype 8 | 96.5 (94.6 to 97.8) | 2.9 (1.6 to 4.6) |
| Serotype 10A | 28.9 (25.2 to 32.8) | 2.7 (1.5 to 4.4) |
| Serotype 11A | 94.2 (91.9 to 96.0) | 2.0 (1.0 to 3.5) |
| Serotype 12F | 30.3 (26.6 to 34.3) | 0.2 (0.0 to 1.0) |
| Serotype 15B | 94.3 (92.1 to 96.1) | 8.5 (6.4 to 11.2) |
| Serotype 22F | 94.4 (92.1 to 96.1) | 2.0 (1.0 to 3.5) |
| Serotype 33F | 46.8 (42.6 to 51.0) | 2.7 (1.5 to 4.4) |
Pneumococcal serotype-specific IgG concentration was measured for serum sample for 13vPnC serotype: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 7 additional serotype: 8, 10A, 11A, 12F, 15B, 22F, 33F. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, corresponding 2-sided 95% CIs (based on Student's t distribution). Assay result below LLOQ was set to 0.5\*LLOQ. Geometric mean ratios (GMRs) were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CIs (based on Student's t distribution).
| Microgram per millilitre (mcg/mL) | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Serotype 1 | 0.57 (0.52 to 0.62) | 0.93 (0.86 to 1.01) |
| Serotype 3 | 0.41 (0.38 to 0.45) | 0.58 (0.54 to 0.63) |
| Serotype 4 | 0.55 (0.50 to 0.61) | 0.92 (0.83 to 1.02) |
| Serotype 5 | 0.34 (0.30 to 0.38) | 0.56 (0.50 to 0.62) |
| Serotype 6A | 0.45 (0.40 to 0.52) | 0.84 (0.73 to 0.95) |
| Serotype 6B | 0.03 (0.03 to 0.04) | 0.06 (0.05 to 0.07) |
| Serotype 7F | 1.02 (0.94 to 1.10) | 1.41 (1.30 to 1.53) |
| Serotype 9V | 0.45 (0.40 to 0.51) | 0.77 (0.68 to 0.87) |
| Serotype 14 | 1.05 (0.94 to 1.18) | 1.28 (1.14 to 1.43) |
| Serotype 18C | 0.69 (0.62 to 0.77) | 0.87 (0.78 to 0.98) |
| Serotype 19A | 0.67 (0.61 to 0.74) | 1.13 (1.01 to 1.26) |
| Serotype 19F | 2.21 (2.04 to 2.40) | 3.06 (2.80 to 3.34) |
| Serotype 23F | 0.13 (0.12 to 0.15) | 0.25 (0.22 to 0.28) |
| Serotype 8 | 1.62 (1.51 to 1.74) | 0.02 (0.02 to 0.02) |
| Serotype 10A | 0.16 (0.14 to 0.18) | 0.02 (0.02 to 0.02) |
| Serotype 11A | 1.62 (1.50 to 1.75) | 0.02 (0.02 to 0.02) |
| Serotype 12F | 0.15 (0.13 to 0.17) | 0.01 (0.01 to 0.01) |
| Serotype 15B | 3.33 (3.00 to 3.70) | 0.04 (0.04 to 0.04) |
| Serotype 22F | 2.25 (2.06 to 2.45) | 0.01 (0.01 to 0.01) |
| Serotype 33F | 0.31 (0.28 to 0.34) | 0.03 (0.02 to 0.03) |
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 7 additional serotype: 8, 10A, 11A, 12F, 15B, 22F,33F. GMC and corresponding 2-sided 95% CI were calculated by exponentiating mean logarithm of concentrations and corresponding 2-sided 95% CI (based on Student's t distribution). Assay result below LLOQ were set to 0.5\*LLOQ. GMRs were reported in statistical analysis section and were calculated by exponentiating mean difference of logarithm of concentration and corresponding 2-sided 95% CI (based on Student's t distribution).
| Microgram per millilitre (mcg/mL) | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Serotype 1 | 1.71 (1.58 to 1.84) | 2.53 (2.33 to 2.75) |
| Serotype 3 | 0.72 (0.67 to 0.78) | 1.09 (1.01 to 1.17) |
| Serotype 4 | 4.11 (3.77 to 4.48) | 5.36 (4.91 to 5.85) |
| Serotype 5 | 1.74 (1.60 to 1.89) | 2.41 (2.21 to 2.64) |
| Serotype 6A | 7.75 (7.04 to 8.53) | 11.82 (10.66 to 13.11) |
| Serotype 6B | 2.64 (2.36 to 2.95) | 4.63 (4.09 to 5.25) |
| Serotype 7F | 3.61 (3.40 to 3.84) | 4.93 (4.63 to 5.24) |
| Serotype 9V | 3.68 (3.42 to 3.97) | 5.04 (4.67 to 5.43) |
| Serotype 14 | 4.52 (4.08 to 5.00) | 5.66 (5.12 to 6.26) |
| Serotype 18C | 2.71 (2.52 to 2.93) | 3.61 (3.33 to 3.91) |
| Serotype 19A | 4.51 (4.11 to 4.94) | 5.49 (5.02 to 6.01) |
| Serotype 19F | 6.19 (5.68 to 6.75) | 8.08 (7.40 to 8.83) |
| Serotype 23F | 2.64 (2.40 to 2.91) | 4.40 (3.95 to 4.90) |
| Serotype 8 | 3.57 (3.32 to 3.83) | 0.03 (0.03 to 0.03) |
| Serotype 10A | 4.86 (4.41 to 5.36) | 0.01 (0.01 to 0.01) |
| Serotype 11A | 3.74 (3.44 to 4.07) | 0.02 (0.01 to 0.02) |
| Serotype 12F | 1.86 (1.71 to 2.01) | 0.01 (0.01 to 0.01) |
| Serotype 15B | 13.09 (12.10 to 14.15) | 0.02 (0.02 to 0.03) |
| Serotype 22F | 9.27 (8.52 to 10.08) | 0.00 (0.00 to 0.00) |
| Serotype 33F | 6.37 (5.83 to 6.95) | 0.01 (0.01 to 0.01) |
Diphtheria and tetanus toxoids: concentration of antibody (AB) (in international units \[IU\]) to diphtheria \& tetanus toxoid (prespecified level\>=0.1 IU/mL); Pertussis antigens-pertussis toxin (PT), filamentous hemagglutinin (FHA), pertactin (PRN): prespecified level \>=observed Anti pertussis Antibody concentration achieved by 95% of 13vPnC recipient; HBsAg prespecified level \>=10 milli-IU per mL (mIU/mL); Poliovirus strains (types 1, 2 and 3): prespecified level: \>=1:8; Hemophilus influenzae type b(Hib): prespecified level \>=0.15 microgram per millilitre (mcg/mL) polyribosylribitol phosphate (anti-PRP) in mcg/mL. Concomitant vaccine response was assessed from subset of randomly selected study participants.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Diphtheria toxoid | 99.6 (98.5 to 100.0) | 99.8 (98.9 to 100.0) |
| Tetanus toxoid | 99.4 (98.2 to 99.9) | 100.0 (99.3 to 100.0) |
| Pertussis: PT | 92.9 (90.3 to 95.0) | 95.2 (92.9 to 96.9) |
| Pertussis: FHA | 95.3 (93.1 to 97.0) | 95.2 (92.9 to 96.9) |
| Pertussis: PRN | 96.8 (94.8 to 98.1) | 95.2 (92.9 to 96.9) |
| Hepatitis B | 100.0 (97.9 to 100.0) | 98.9 (96.0 to 99.9) |
| Poliovirus: Type 1 | 100.0 (95.5 to 100.0) | 100.0 (95.9 to 100.0) |
| Poliovirus: Type 2 | 100.0 (95.5 to 100.0) | 100.0 (95.9 to 100.0) |
| Poliovirus: Type 3 | 100.0 (95.5 to 100.0) | 100.0 (95.9 to 100.0) |
| Hemophilus influenzae type b | 100.0 (98.0 to 100.0) | 100.0 (97.8 to 100.0) |
Pre-specified vaccine antigen (measles) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.
| Arbitrary units per millilitre | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| GMC of Measles Virus Antibody 1 Month After Dose 3: Primary Study Population | 228.63 ± 186.34 | 216.72 ± 174.92 |
Pre-specified vaccine antigen (mumps) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.
| Arbitrary units per millilitre | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| GMC of Mumps Virus Antibody 1 Month After Dose 3: Primary Study Population | 36.81 ± 29.12 | 35.25 ± 28.14 |
Pre-specified vaccine antigen (rubella) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.
| International units per millilitre | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| GMC of Rubella Virus Antibody 1 Month After Dose 3: Primary Study Population | 31.81 ± 25.54 | 38.20 ± 32.10 |
Pre-specified vaccine antigen (varicella) was administered concomitantly with 20vPnC or 13vPnC at Dose 3 and responses were measured 1 month after Dose 3. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMCs and 2-sided 95% CIs were calculated by exponentiating the mean logarithm of the concentrations and the corresponding CIs (based on the Student's t distribution). The immune responses were only measured on random subset of participants.
| Milli-international units per millilitre | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| GMC of Varicella Virus Antibody 1 Month After Dose 3: Primary Study Population | 195.58 ± 165.14 | 157.60 ± 133.57 |
Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\> 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Redness: Mild | 4.2 ± 0.1 | 7.4 ± 0.9 |
| Redness: Moderate | 4.2 ± 0.1 | 3.7 ± 0.1 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Mild | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Moderate | 4.2 ± 0.1 | 0 ± 0.0 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Pain at Injection Site: Mild | 8.3 ± 1.0 | 7.4 ± 0.9 |
| Pain at Injection Site: Moderate | 0 ± 0.0 | 3.7 ± 0.1 |
| Pain at Injection Site: Severe | 0 ± 0.0 | 0 ± 0.0 |
Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\> 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Redness: Mild | 0 ± 0.0 | 3.7 ± 0.1 |
| Redness: Moderate | 4.3 ± 0.1 | 0 ± 0.0 |
| Redness: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Swelling: Mild | 0 ± 0.0 | 7.4 ± 0.9 |
| Swelling: Moderate | 8.7 ± 1.1 | 0 ± 0.0 |
| Swelling: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Pain at Injection Site: Mild | 8.7 ± 1.1 | 7.4 ± 0.9 |
| Pain at Injection Site: Moderate | 4.3 ± 0.1 | 0 ± 0.0 |
| Pain at Injection Site: Severe | 0 ± 0.0 | 0 ± 0.0 |
Local reactions included redness, swelling and, pain at the injection site, recorded by parents/legal guardians of participants in an e-diary. Redness and swelling were measured and recorded in measuring device units. 1 measuring device unit =0.5 cm. Redness and swelling were graded as mild (\>0 to 2.0 cm), moderate (\> 2.0 to 7.0 cm) and severe (\>7.0 cm). Pain at injection site was graded as mild (hurt if gently touched example, whimpered, winced, protested, or withdrew), moderate (hurt if gently touched, with crying), and severe (caused limitation of limb movement). 95% CI was based on Clopper and Pearson method.
| Percentage of participants | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Redness: Mild | 0 (0.0 to 15.4) | 4.0 (0.1 to 20.4) |
| Redness: Moderate | 4.5 (0.1 to 22.8) | 0 (0.0 to 13.7) |
| Redness: Severe | 0 (0.0 to 15.4) | 4.0 (0.1 to 20.4) |
| Swelling: Mild | 0 (0.0 to 15.4) | 0 (0.0 to 13.7) |
| Swelling: Moderate | 9.1 (1.1 to 29.2) | 0 (0.0 to 13.7) |
| Swelling: Severe | 0 (0.0 to 15.4) | 4.0 (0.1 to 20.4) |
| Pain at Injection Site: Mild | 13.6 (2.9 to 34.9) | 8.0 (1.0 to 26.0) |
| Pain at Injection Site: Moderate | 0 (0.0 to 15.4) | 0 (0.0 to 13.7) |
| Pain at Injection Site: Severe | 0 (0.0 to 15.4) | 0 (0.0 to 13.7) |
Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participant's using e-diary. Fever: temperature \>=38.0 degree C \& categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: was graded as mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.
| Percentage of participants | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Fever: >=38.0 degrees C to 38.4 degrees C | 4.2 ± 0.1 | 0 ± 0.0 |
| Fever: >38.4 degrees C to 38.9 degrees C | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.9 degrees C to 40.0 degrees C | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >40.0 degrees C | 0 ± 0.0 | 0 ± 0.0 |
| Decreased appetite: Mild | 16.7 ± 4.7 | 14.8 ± 4.2 |
| Decreased appetite: Moderate | 0 ± 0.0 | 3.7 ± 0.1 |
| Decreased appetite: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Drowsiness: Mild | 20.8 ± 7.1 | 18.5 ± 6.3 |
| Drowsiness: Moderate | 8.3 ± 1.0 | 11.1 ± 2.4 |
| Drowsiness: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Irritability: Mild | 12.5 ± 2.7 | 7.4 ± 0.9 |
| Irritability: Moderate | 8.3 ± 1.0 | 14.8 ± 4.2 |
| Irritability: Severe | 4.2 ± 0.1 | 0 ± 0.0 |
Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.
| Percentage of participants | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Fever: >=38.0 degrees C to 38.4 degrees C | 0 ± 0.0 | 11.1 ± 2.4 |
| Fever: >38.4 degrees C to 38.9 degrees C | 4.3 ± 0.1 | 0 ± 0.0 |
| Fever: >38.9 degrees C to 40.0 degrees C | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >40.0 degrees C | 0 ± 0.0 | 0 ± 0.0 |
| Decreased appetite: Mild | 4.3 ± 0.1 | 7.4 ± 0.9 |
| Decreased appetite: Moderate | 4.3 ± 0.1 | 3.7 ± 0.1 |
| Decreased appetite: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Drowsiness: Mild | 4.3 ± 0.1 | 3.7 ± 0.1 |
| Drowsiness: Moderate | 0 ± 0.0 | 3.7 ± 0.1 |
| Drowsiness: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Irritability: Mild | 13.0 ± 2.8 | 22.2 ± 8.6 |
| Irritability: Moderate | 4.3 ± 0.1 | 18.5 ± 6.3 |
| Irritability: Severe | 0 ± 0.0 | 3.7 ± 0.1 |
Systemic events: fever, decreased appetite, drowsiness/increased sleep and irritability, recorded by parents/legal guardians of participants using an e-diary. Fever: temperature \>=38.0 degree C and categorized as \>=38.0 to 38.4 degree C, \>38.4 to 38.9 degree C, \>38.9 to 40.0 degree C and \>40.0-degree C. Decreased appetite: mild (decreased interest in eating), moderate (decreased oral intake) and severe (refusal to feed). Drowsiness was graded as mild (increased/prolonged sleeping bouts), moderate (slightly subdued, interfered with daily activity) and severe (disabling, not interested in usual daily activity). Irritability: mild (easily consolable), moderate (required increased attention) and severe (inconsolable, crying could not be comforted). 95% CI was based on Clopper \& Pearson method.
| Percentage of participants | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Fever: >=38.0 degrees C to 38.4 degrees C | 0 ± 0.0 | 0 ± 0.0 |
| Fever: >38.4 degrees C to 38.9 degrees C | 0 ± 0.0 | 4.0 ± 0.1 |
| Fever: >38.9 degrees C to 40.0 degrees C | 4.5 ± 0.1 | 0 ± 0.0 |
| Fever: >40.0 degrees C | 0 ± 0.0 | 0 ± 0.0 |
| Decreased appetite: Mild | 9.1 ± 1.1 | 8.0 ± 1.0 |
| Decreased appetite: Moderate | 9.1 ± 1.1 | 0 ± 0.0 |
| Decreased appetite: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Drowsiness: Mild | 13.6 ± 2.9 | 20.0 ± 6.8 |
| Drowsiness: Moderate | 0 ± 0.0 | 4.0 ± 0.1 |
| Drowsiness: Severe | 0 ± 0.0 | 0 ± 0.0 |
| Irritability: Mild | 27.3 ± 10.7 | 16.0 ± 4.5 |
| Irritability: Moderate | 9.1 ± 1.1 | 8.0 ± 1.0 |
| Irritability: Severe | 0 ± 0.0 | 0 ± 0.0 |
An AE was any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.
| Percentage of participants | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Percentage of Participants With AEs From Dose 1 to 1 Month After Dose 2: Russian Cohort | 8.3 ± 1.0 | 3.7 ± 0.1 |
An AE was any untoward medical occurrence in a participants, temporally associated with the use of study treatment, whether or not considered related to the study treatment. 95% CI was based on the Clopper and Pearson method. AEs reported in this outcome measure excluded local reactions and systemic events collected from an e-diary.
| Percentage of participants | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Percentage of Participants With AEs From Dose 3 to 1 Month After Dose 3: Russian Cohort | 4.5 ± 0.1 | 0 ± 0.0 |
A SAE was any untoward medical occurrence that, at any dose: resulted in death; required inpatient hospitalization or prolongation of existing hospitalization; was life-threatening; resulted in persistent or significant disability/ incapacity; was a congenital anomaly/birth defect and other important medical events. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Percentage of Participants With SAEs From Dose 1 to 1 Month After Dose 3: Russian Cohort | 0 (0 to 14.2) | 0 (0 to 12.8) |
A NDCMC was defined as a disease or medical condition, not previously identified, that was expected to be persistent or was otherwise long-lasting in its effects. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Percentage of Participants With NDCMC From Dose 1 to 1 Month After Dose 3: Russian Cohort | 0 (0 to 14.2) | 0 (0 to 12.8) |
Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 mcg/mL, for serotype 5: \>=0.23 mcg/mL, for serotype 6B. \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Serotype 1 | 70.8 ± 48.9 | 77.8 ± 57.7 |
| Serotype 3 | 37.5 ± 18.8 | 59.3 ± 38.8 |
| Serotype 4 | 75.0 ± 53.3 | 74.1 ± 53.7 |
| Serotype 5 | 66.7 ± 44.7 | 81.5 ± 61.9 |
| Serotype 6A | 54.2 ± 32.8 | 81.5 ± 61.9 |
| Serotype 6B | 20.8 ± 7.1 | 59.3 ± 38.8 |
| Serotype 7F | 95.8 ± 78.9 | 92.6 ± 75.7 |
| Serotype 9V | 41.7 ± 22.1 | 81.5 ± 61.9 |
| Serotype 14 | 83.3 ± 62.6 | 85.2 ± 66.3 |
| Serotype 18C | 66.7 ± 44.7 | 81.5 ± 61.9 |
| Serotype 19A | 87.5 ± 67.6 | 92.6 ± 75.7 |
| Serotype 19F | 79.2 ± 57.8 | 96.3 ± 81.0 |
| Serotype 23F | 37.5 ± 18.8 | 70.4 ± 49.8 |
| Serotype 8 | 75.0 ± 53.3 | 33.3 ± 16.5 |
| Serotype 10A | 41.7 ± 22.1 | 18.5 ± 6.3 |
| Serotype 11A | 83.3 ± 62.6 | 18.5 ± 6.3 |
| Serotype 12F | 12.5 ± 2.7 | 14.8 ± 4.2 |
| Serotype 15B | 66.7 ± 44.7 | 33.3 ± 16.5 |
| Serotype 22F | 66.7 ± 44.7 | 14.8 ± 4.2 |
| Serotype 33F | 45.8 ± 25.6 | 25.9 ± 11.1 |
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and 7 additional serotypes: 8, 10A, 11A, 12F, 15B, 22F, 33F. Assay results below the LLOQ were set to 0.5 \* LLOQ. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, and the corresponding 2-sided 95% CIs (based on Student's t distribution).
| Microgram per millilitre (mcg/mL) | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Serotype 1 | 0.76 ± 0.49 | 1.04 ± 0.64 |
| Serotype 3 | 0.28 ± 0.19 | 0.47 ± 0.31 |
| Serotype 4 | 0.67 ± 0.45 | 1.00 ± 0.58 |
| Serotype 5 | 0.53 ± 0.31 | 0.75 ± 0.40 |
| Serotype 6A | 0.45 ± 0.20 | 1.57 ± 0.80 |
| Serotype 6B | 0.07 ± 0.03 | 0.27 ± 0.12 |
| Serotype 7F | 1.06 ± 0.68 | 1.89 ± 1.32 |
| Serotype 9V | 0.44 ± 0.23 | 1.22 ± 0.73 |
| Serotype 14 | 1.56 ± 0.88 | 2.66 ± 1.46 |
| Serotype 18C | 0.94 ± 0.46 | 0.94 ± 0.50 |
| Serotype 19A | 1.15 ± 0.47 | 1.21 ± 0.59 |
| Serotype 19F | 1.51 ± 0.84 | 3.32 ± 2.03 |
| Serotype 23F | 0.25 ± 0.11 | 0.73 ± 0.37 |
| Serotype 8 | 0.79 ± 0.37 | 0.07 ± 0.03 |
| Serotype 10A | 0.31 ± 0.10 | 0.04 ± 0.01 |
| Serotype 11A | 0.83 ± 0.43 | 0.04 ± 0.02 |
| Serotype 12F | 0.06 ± 0.03 | 0.02 ± 0.01 |
| Serotype 15B | 1.19 ± 0.46 | 0.16 ± 0.05 |
| Serotype 22F | 0.48 ± 0.16 | 0.02 ± 0.01 |
| Serotype 33F | 0.40 ± 0.18 | 0.07 ± 0.03 |
Pneumococcal serotype-specific IgG concentrations were measured for serum samples for 13vPnC serotypes: 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F and additional serotypes: 8, 10A, 11A, 12F, 15B, 22F and 33F. Assay results below the LLOQ were set to 0.5 \* LLOQ. GMC and corresponding 2-sided 95% CIs were calculated by exponentiating mean logarithm of concentration, and the corresponding 2-sided 95% CIs (based on Student's t distribution).
| Microgram per millilitre (mcg/mL) | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Serotype 1 | 1.61 ± 0.93 | 1.65 ± 0.94 |
| Serotype 3 | 0.84 ± 0.44 | 0.57 ± 0.32 |
| Serotype 4 | 3.05 ± 1.50 | 3.04 ± 1.72 |
| Serotype 5 | 1.50 ± 0.80 | 1.72 ± 0.90 |
| Serotype 6A | 6.63 ± 2.96 | 5.63 ± 2.96 |
| Serotype 6B | 1.94 ± 0.82 | 1.49 ± 0.67 |
| Serotype 7F | 3.53 ± 1.97 | 4.14 ± 2.73 |
| Serotype 9V | 2.32 ± 1.28 | 2.27 ± 1.19 |
| Serotype 14 | 4.01 ± 1.64 | 5.06 ± 3.04 |
| Serotype 18C | 2.60 ± 1.24 | 2.64 ± 1.49 |
| Serotype 19A | 4.81 ± 2.07 | 2.69 ± 1.12 |
| Serotype 19F | 4.97 ± 2.30 | 4.58 ± 2.36 |
| Serotype 23F | 3.52 ± 1.68 | 2.96 ± 1.33 |
| Serotype 8 | 1.33 ± 0.50 | 0.09 ± 0.04 |
| Serotype 10A | 1.99 ± 0.63 | 0.03 ± 0.01 |
| Serotype 11A | 1.50 ± 0.58 | 0.06 ± 0.02 |
| Serotype 12F | 0.17 ± 0.05 | 0.02 ± 0.01 |
| Serotype 15B | 4.90 ± 1.67 | 0.07 ± 0.03 |
| Serotype 22F | 1.52 ± 0.38 | 0.02 ± 0.01 |
| Serotype 33F | 1.38 ± 0.53 | 0.04 ± 0.02 |
Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 mcg/mL, for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Serotype 1 | 97.2 (95.3 to 98.4) | 98.2 (96.6 to 99.2) |
| Serotype 3 | 82.6 (79.0 to 85.8) | 93.2 (90.7 to 95.3) |
| Serotype 4 | 99.2 (97.9 to 99.8) | 99.2 (98.0 to 99.8) |
| Serotype 5 | 98.4 (96.8 to 99.3) | 98.0 (96.4 to 99.0) |
| Serotype 6A | 98.8 (97.4 to 99.6) | 98.8 (97.4 to 99.6) |
| Serotype 6B | 98.4 (96.8 to 99.3) | 97.6 (95.9 to 98.8) |
| Serotype 7F | 99.6 (98.5 to 100.0) | 100.0 (99.3 to 100.0) |
| Serotype 9V | 99.2 (97.9 to 99.8) | 98.8 (97.4 to 99.6) |
| Serotype 14 | 96.6 (94.5 to 98.0) | 98.0 (96.4 to 99.0) |
| Serotype 18C | 99.2 (97.9 to 99.8) | 98.2 (96.6 to 99.2) |
| Serotype 19A | 99.6 (98.5 to 100.0) | 99.6 (98.6 to 100.0) |
| Serotype 19F | 99.6 (98.5 to 100.0) | 99.4 (98.3 to 99.9) |
| Serotype 23F | 96.4 (94.3 to 97.8) | 97.2 (95.4 to 98.5) |
| Serotype 8 | 99.2 (97.9 to 99.8) | 3.6 (2.1 to 5.6) |
| Serotype 10A | 97.8 (96.1 to 98.9) | 1.6 (0.7 to 3.1) |
| Serotype 11A | 98.4 (96.8 to 99.3) | 4.6 (2.9 to 6.8) |
| Serotype 12F | 96.6 (94.6 to 98.0) | 0.2 (0.0 to 1.1) |
| Serotype 15B | 99.4 (98.2 to 99.9) | 4.8 (3.1 to 7.0) |
| Serotype 22F | 99.2 (97.9 to 99.8) | 1.4 (0.6 to 2.9) |
| Serotype 33F | 98.6 (97.1 to 99.4) | 1.8 (0.8 to 3.4) |
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 2. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the Student's t distribution.
| Titers | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Serotype 1 | 14 (12 to 16) | 23 (19 to 28) |
| Serotype 3 | 31 (26 to 36) | 40 (34 to 47) |
| Serotype 4 | 333 (270 to 413) | 391 (314 to 486) |
| Serotype 5 | 21 (18 to 23) | 27 (23 to 31) |
| Serotype 6A | 347 (273 to 441) | 409 (318 to 527) |
| Serotype 6B | 54 (42 to 71) | 105 (76 to 144) |
| Serotype 7F | 858 (736 to 1000) | 895 (781 to 1027) |
| Serotype 9V | 233 (182 to 298) | 285 (228 to 358) |
| Serotype 14 | 287 (215 to 383) | 360 (264 to 489) |
| Serotype 18C | 588 (467 to 741) | 719 (590 to 876) |
| Serotype 19A | 57 (43 to 75) | 91 (69 to 121) |
| Serotype 19F | 97 (81 to 116) | 117 (94 to 146) |
| Serotype 23F | 59 (42 to 84) | 68 (48 to 96) |
| Serotype 8 | 164 (133 to 203) | 17 (15 to 18) |
| Serotype 10A | 855 (610 to 1199) | 39 (34 to 44) |
| Serotype 11A | 327 (253 to 423) | 49 (47 to 51) |
| Serotype 12F | 4788 (3779 to 6067) | 26 (23 to 28) |
| Serotype 15B | 846 (605 to 1183) | 17 (15 to 19) |
| Serotype 22F | 4444 (3666 to 5386) | 10 (9 to 11) |
| Serotype 33F | 2373 (1759 to 3202) | 178 (163 to 195) |
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 3. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the Student's t distribution.
| Titers | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Serotype 1 | 54 (43 to 69) | 101 (79 to 129) |
| Serotype 3 | 99 (84 to 117) | 129 (111 to 150) |
| Serotype 4 | 904 (752 to 1086) | 992 (777 to 1266) |
| Serotype 5 | 60 (50 to 72) | 82 (66 to 101) |
| Serotype 6A | 1101 (897 to 1350) | 1304 (1018 to 1671) |
| Serotype 6B | 537 (408 to 706) | 864 (664 to 1125) |
| Serotype 7F | 1811 (1553 to 2112) | 2197 (1905 to 2533) |
| Serotype 9V | 3254 (2596 to 4079) | 4544 (3681 to 5610) |
| Serotype 14 | 738 (606 to 899) | 926 (751 to 1142) |
| Serotype 18C | 1296 (1048 to 1602) | 1870 (1489 to 2348) |
| Serotype 19A | 754 (627 to 907) | 707 (558 to 896) |
| Serotype 19F | 183 (140 to 237) | 258 (192 to 347) |
| Serotype 23F | 697 (530 to 917) | 975 (734 to 1296) |
| Serotype 8 | 1398 (1088 to 1796) | 31 (25 to 39) |
| Serotype 10A | 3403 (2600 to 4455) | 69 (52 to 91) |
| Serotype 11A | 2966 (2212 to 3978) | 66 (51 to 85) |
| Serotype 12F | 5501 (4499 to 6725) | 29 (25 to 35) |
| Serotype 15B | 2676 (1948 to 3677) | 23 (18 to 30) |
| Serotype 22F | 6523 (4848 to 8777) | 17 (13 to 24) |
| Serotype 33F | 11315 (8107 to 15794) | 708 (545 to 920) |
20vPnC serotypes included: 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. Assay results below the LLOQ were set to 0.5\*LLOQ in the analysis. GMFRs and the corresponding 2-sided CIs were calculated by exponentiating the mean logarithm of the fold rises and the corresponding CIs (based on the Student's t distribution).
| Fold rise | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Serotype 1 | 13.9 (12.7 to 15.3) | 13.9 (12.8 to 15.1) |
| Serotype 3 | 13.7 (12.4 to 15.1) | 15.2 (13.9 to 16.7) |
| Serotype 4 | 29.8 (27.0 to 32.9) | 27.7 (25.0 to 30.6) |
| Serotype 5 | 14.0 (12.9 to 15.2) | 13.6 (12.6 to 14.7) |
| Serotype 6A | 26.9 (24.2 to 30.0) | 28.7 (25.9 to 31.7) |
| Serotype 6B | 36.8 (33.3 to 40.6) | 40.2 (36.8 to 44.0) |
| Serotype 7F | 8.5 (7.9 to 9.2) | 9.3 (8.6 to 10.0) |
| Serotype 9V | 22.5 (20.4 to 24.7) | 19.9 (18.3 to 21.6) |
| Serotype 14 | 9.7 (8.7 to 10.8) | 8.4 (7.6 to 9.4) |
| Serotype 18C | 15.8 (14.5 to 17.1) | 17.0 (15.7 to 18.4) |
| Serotype 19A | 39.3 (34.6 to 44.7) | 40.7 (36.4 to 45.5) |
| Serotype 19F | 20.5 (18.4 to 22.9) | 21.4 (19.4 to 23.7) |
| Serotype 23F | 32.3 (29.2 to 35.7) | 38.3 (34.7 to 42.4) |
| Serotype 8 | 12.7 (11.6 to 13.9) | 1.4 (1.3 to 1.5) |
| Serotype 10A | 14.8 (13.3 to 16.4) | 1.1 (1.0 to 1.2) |
| Serotype 11A | 13.8 (12.4 to 15.3) | 1.1 (1.0 to 1.2) |
| Serotype 12F | 16.5 (15.0 to 18.0) | 1.0 (1.0 to 1.1) |
| Serotype 15B | 13.4 (11.9 to 15.1) | 1.3 (1.2 to 1.4) |
| Serotype 22F | 12.8 (11.5 to 14.3) | 1.3 (1.1 to 1.4) |
| Serotype 33F | 12.9 (11.6 to 14.3) | 1.1 (1.0 to 1.2) |
Pre-specified vaccines were administered concomitantly with 20vPnC or 13vPnC and responses assessed using pre-defined levels as follows: Diphtheria and tetanus toxoids: concentration of antibody (in international units \[IU\]) to diphtheria and tetanus toxoid (prespecified level \>= observed anti-pertussis antibody concentration achieved by 95% of 13vPnC recipients); Poliomyelitis: NA titers to poliovirus types 1, 2, and 3 (prespecified level NA titer \>=1:8); and Hib: concentration of antibody to Hib (PRP) in mcg/mL (prespecified level \>=0.15 mcg/mL anti-PRP). 2-sided 95% CI was based on Clopper and Pearson method. The assays were performed on randomly selected subsets.
| Percentage of participants | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population |
|---|---|---|
| Diphtheria toxoid | 85.0 (79.3 to 89.6) | 89.5 (84.4 to 93.4) |
| Tetanus toxoid | 95.5 (91.6 to 97.9) | 98.5 (95.7 to 99.7) |
| Pertussis: PT | 94.5 (90.4 to 97.2) | 95.0 (91.0 to 97.6) |
| Pertussis: FHA | 93.5 (89.1 to 96.5) | 95.0 (91.0 to 97.6) |
| Pertussis: PRN | 93.5 (89.1 to 96.5) | 95.0 (91.0 to 97.6) |
| Poliovirus: Type 1 | 94.8 (88.3 to 98.3) | 98.1 (93.2 to 99.8) |
| Poliovirus: Type 2 | 88.5 (80.4 to 94.1) | 91.3 (84.2 to 96.0) |
| Poliovirus: Type 3 | 95.8 (89.7 to 98.9) | 100.0 (96.5 to 100.0) |
| Hemophilus influenzae type b | 100.0 (98.2 to 100.0) | 100.0 (98.1 to 100.0) |
Predefined IgG concentrations were as follows: for serotype 1, 3, 4, 6A, 7F, 9V, 14, 18C, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, 33F: \>=0.35 mcg/mL, for serotype 5: \>=0.23 mcg/mL, for serotype 6B: \>=0.10 mcg/mL and for serotype 19A: \>=0.12 mcg/mL. 95% CI was based on the Clopper and Pearson method.
| Percentage of participants | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Serotype 1 | 90.9 (70.8 to 98.9) | 83.3 (62.6 to 95.3) |
| Serotype 3 | 68.2 (45.1 to 86.1) | 50.0 (29.1 to 70.9) |
| Serotype 4 | 95.5 (77.2 to 99.9) | 100.0 (85.8 to 100.0) |
| Serotype 5 | 90.9 (70.8 to 98.9) | 91.7 (73.0 to 99.0) |
| Serotype 6A | 95.5 (77.2 to 99.9) | 100.0 (85.8 to 100.0) |
| Serotype 6B | 90.9 (70.8 to 98.9) | 91.7 (73.0 to 99.0) |
| Serotype 7F | 95.5 (77.2 to 99.9) | 100.0 (85.8 to 100.0) |
| Serotype 9V | 100.0 (84.6 to 100.0) | 83.3 (62.6 to 95.3) |
| Serotype 14 | 90.9 (70.8 to 98.9) | 100.0 (85.8 to 100.0) |
| Serotype 18C | 90.9 (70.8 to 98.9) | 95.8 (78.9 to 99.9) |
| Serotype 19A | 100.0 (84.6 to 100.0) | 95.8 (78.9 to 99.9) |
| Serotype 19F | 100.0 (84.6 to 100.0) | 91.7 (73.0 to 99.0) |
| Serotype 23F | 90.9 (70.8 to 98.9) | 79.2 (57.8 to 92.9) |
| Serotype 8 | 68.2 (45.1 to 86.1) | 25.0 (9.8 to 46.7) |
| Serotype 10A | 68.2 (45.1 to 86.1) | 16.7 (4.7 to 37.4) |
| Serotype 11A | 77.3 (54.6 to 92.2) | 20.8 (7.1 to 42.2) |
| Serotype 12F | 36.4 (17.2 to 59.3) | 4.2 (0.1 to 21.1) |
| Serotype 15B | 90.9 (70.8 to 98.9) | 20.8 (7.1 to 42.2) |
| Serotype 22F | 63.6 (40.7 to 82.8) | 12.5 (2.7 to 32.4) |
| Serotype 33F | 72.7 (49.8 to 89.3) | 20.8 (7.1 to 42.2) |
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 2. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the student's t distribution.
| Titers | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Serotype 1 | 17 (7 to 40) | 33 (10 to 105) |
| Serotype 3 | 79 (42 to 149) | 31 (13 to 73) |
| Serotype 4 | 166 (38 to 736) | 163 (32 to 840) |
| Serotype 5 | 28 (11 to 76) | 31 (14 to 71) |
| Serotype 6A | 222 (32 to 1553) | 247 (60 to 1011) |
| Serotype 6B | 314 (27 to 3584) | 216 (39 to 1186) |
| Serotype 7F | 809 (481 to 1361) | 717 (246 to 2084) |
| Serotype 9V | 218 (70 to 676) | 293 (85 to 1008) |
| Serotype 14 | 984 (492 to 1970) | 247 (69 to 886) |
| Serotype 18C | 968 (403 to 2326) | 268 (43 to 1655) |
| Serotype 19A | 314 (68 to 1443) | 31 (8 to 118) |
| Serotype 19F | 120 (27 to 529) | 230 (48 to 1097) |
| Serotype 23F | 35 (6 to 196) | 56 (9 to 346) |
| Serotype 8 | 203 (19 to 2155) | 38 (9 to 161) |
| Serotype 10A | 559 (50 to 6233) | 232 (8 to 6478) |
| Serotype 11A | 3537 (863 to 14497) | 2717 (470 to 15716) |
| Serotype 12F | 698 (77 to 6301) | 198 (41 to 960) |
| Serotype 15B | 142 (9 to 2269) | 242 (18 to 3267) |
| Serotype 22F | 413 (32 to 5406) | 499 (28 to 8837) |
| Serotype 33F | 3508 (349 to 35250) | 3961 (706 to 22238) |
OPA titers for the 20 pneumococcal serotypes (1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 23F, 8, 10A, 11A, 12F, 15B, 22F, and 33F) were determined in randomly selected subsets of participants at 1 month after Dose 3. Results were expressed as OPA titers. GMTs and 2-sided CIs were calculated by exponentiating the mean logarithm of the titers and the corresponding CIs based on the student's t distribution.
| Titers | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|
| Serotype 1 | 85 (17 to 421) | 93 (22 to 394) |
| Serotype 3 | 126 (41 to 383) | 107 (37 to 309) |
| Serotype 4 | 310 (86 to 1123) | 429 (38 to 4863) |
| Serotype 5 | 116 (28 to 476) | 108 (26 to 456) |
| Serotype 6A | 2922 (311 to 27459) | 1580 (393 to 6351) |
| Serotype 6B | 4417 (998 to 19951) | 1397 (150 to 12967) |
| Serotype 7F | 1039 (509 to 2122) | 1411 (373 to 5340) |
| Serotype 9V | 1574 (369 to 6711) | 1067 (150 to 7583) |
| Serotype 14 | 1151 (321 to 4132) | 628 (137 to 2890) |
| Serotype 18C | 583 (149 to 2284) | 973 (89 to 10606) |
| Serotype 19A | 652 (131 to 3234) | 435 (14 to 13833) |
| Serotype 19F | 1570 (239 to 10337) | 701 (124 to 3958) |
| Serotype 23F | 152 (24 to 966) | 410 (22 to 7594) |
| Serotype 8 | 368 (11 to 12078) | 149 (9 to 2337) |
| Serotype 10A | 2851 (1309 to 6210) | 117 (15 to 916) |
| Serotype 11A | 7137 (1036 to 49164) | 1789 (36 to 89068) |
| Serotype 12F | 757 (15 to 37522) | 241 (16 to 3734) |
| Serotype 15B | 822 (42 to 16070) | 147 (10 to 2214) |
| Serotype 22F | 1983 (390 to 10085) | 1635 (165 to 16157) |
| Serotype 33F | 5903 (53 to 657862) | 3619 (948 to 13817) |
Collected over Local reactions and Systemic events (systematic assessment): Within 7 days after Dose 1, 2, or 3; SAEs (non-systematic assessment): From Dose 1 up to 1 month after Dose 3 and other AEs (non-systematic assessment): From Dose 1 up to 1 month after Dose 2 and from Dose 3 up to 1 month after Dose 3. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 20vPnC: Primary Study Population | 0/601 (0%) | 34/601 (5.7%) | 589/601 (98%) |
| 13vPnC: Primary Study Population | 0/603 (0%) | 40/603 (6.6%) | 593/603 (98.3%) |
| 20vPnC: Russian Cohort | 0/24 (0%) | 0/24 (0%) | 17/24 (70.8%) |
| 13vPnC: Russian Cohort | 0/27 (0%) | 0/27 (0%) | 20/27 (74.1%) |
| Event | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|---|---|
| GastroenteritisInfections and infestations | 4/601 | 5/603 | 0/24 | 0/27 |
| Urinary tract infectionInfections and infestations | 4/601 | 4/603 | 0/24 | 0/27 |
| Viral infectionInfections and infestations | 3/601 | 1/603 | 0/24 | 0/27 |
| PneumoniaInfections and infestations | 1/601 | 3/603 | 0/24 | 0/27 |
| Feeding disorderMetabolism and nutrition disorders | 0/601 | 3/603 | 0/24 | 0/27 |
| BronchiolitisInfections and infestations | 2/601 | 2/603 | 0/24 | 0/27 |
| Gastrointestinal infectionInfections and infestations | 2/601 | 2/603 | 0/24 | 0/27 |
| Respiratory syncytial virus bronchiolitisInfections and infestations | 2/601 | 1/603 | 0/24 | 0/27 |
| Escherichia urinary tract infectionInfections and infestations | 0/601 | 2/603 | 0/24 | 0/27 |
| LaryngitisInfections and infestations | 1/601 | 2/603 | 0/24 | 0/27 |
| Event | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort |
|---|---|---|---|---|
| Irritability (IRRITABILITY)Psychiatric disorders | 553/601 | 556/603 | 13/24 | 15/27 |
| Hypersomnia (INCREASED SLEEP)Nervous system disorders | 495/601 | 512/603 | 8/24 | 11/27 |
| Injection site pain (PAIN)General disorders | 343/601 | 347/603 | 7/24 | 6/27 |
| Decreased appetite (DECREASED APPETITE)Metabolism and nutrition disorders | 345/601 | 323/603 | 9/24 | 8/27 |
| Injection site erythema (REDNESS)General disorders | 331/601 | 333/603 | 3/24 | 4/27 |
| Injection site swelling (SWELLING)General disorders | 260/601 | 251/603 | 4/24 | 3/27 |
| Pyrexia (FEVER)General disorders | 212/601 | 214/603 | 2/24 | 4/27 |
| Upper respiratory tract infectionInfections and infestations | 21/601 | 35/603 | 1/24 | 0/27 |
Safety analysis set included all participants who received at least 1 dose of 20vPnC or 13vPnC and had safety data assessed after any dose.
| Age, Customized(Participants) | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort | Total |
|---|---|---|---|---|---|
| 28 days-23 months | 601 | 603 | 24 | 27 | 1255 |
| Sex: Female, Male(Participants) | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort | Total |
|---|---|---|---|---|---|
| Female | 302 | 292 | 16 | 12 | 622 |
| Male | 299 | 311 | 8 | 15 | 633 |
| Ethnicity (NIH/OMB)(Participants) | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 4 | 1 | 0 | 0 | 5 |
| Not Hispanic or Latino | 577 | 586 | 22 | 25 | 1210 |
| Unknown or Not Reported | 20 | 16 | 2 | 2 | 40 |
| Race (NIH/OMB)(Participants) | 20vPnC: Primary Study Population | 13vPnC: Primary Study Population | 20vPnC: Russian Cohort | 13vPnC: Russian Cohort | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 8 | 5 | 0 | 1 | 14 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 0 | 1 | 0 | 0 | 1 |
| White | 585 | 592 | 24 | 26 | 1227 |
| More than one race | 1 | 0 | 0 | 0 | 1 |
| Unknown or Not Reported | 7 | 5 | 0 | 0 | 12 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Sep 2020 to primary completion in Apr 2022, 19 months.
Results were first posted in May 2023, 1 year after primary completion.
Of 81 industry-sponsored phase 3 interventional studies under Pneumococcal Infections, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 23. This study's 19 months is above that.
Counting every sponsor, half of 82 studies reached it within 13 months; a quarter within 9 and three quarters within 23.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Pneumococcal 20-Valent Conjugate Vaccine